Nov 2, 4:05 PM ET
Sabra Health Care REIT reported third quarter 2026 total revenues of $249.6 million, up from $190.0 million a year earlier, and net income of $0.11 per diluted share, compared with $0.09. Normalized FFO was $0.39 per diluted share, up from $0.36, and the company updated 2026 normalized FFO guidance to $1.540 to $1.550 per share, which its CEO said was increased at the midpoint.
- Total revenues were $249.6 million for the quarter, versus $190.0 million in the third quarter of 2025.
- Normalized FFO was $0.39 per diluted share, versus $0.36; normalized AFFO was $0.41, versus $0.38.
- Full-year 2026 guidance: net income $0.265 to $0.275 per share and normalized FFO $1.540 to $1.550 per share.
- Sabra was awarded an additional $425 million of investments and declared a quarterly dividend of $0.30 per share, payable November 30, 2026.
Read the filing on SEC.gov ↗
Aug 3, 4:05 PM ET
Sabra Health Care REIT reported a second-quarter 2026 net loss of $0.10 per diluted share, compared with net income of $0.27 per diluted share a year earlier, after a $102.4 million provision for loan losses and other reserves. Total revenues rose to $235.9 million from $189.2 million, and normalized FFO per diluted share was $0.38 versus $0.37, while the company reiterated its full-year 2026 guidance.
- Q2 2026 net loss of $0.10 per diluted share vs. net income of $0.27 in Q2 2025
- Total revenues of $235.9 million vs. $189.2 million in Q2 2025; provision for loan losses and other reserves of $102.4 million
- Normalized FFO of $0.38 per diluted share vs. $0.37; normalized AFFO of $0.40 vs. $0.38
- Full-year 2026 guidance reiterated; quarterly dividend of $0.30 per share payable August 31, 2026
Read the filing on SEC.gov ↗
Apr 29, 4:05 PM ET
Sabra reported first quarter 2026 results, with total revenues of $221.8 million, up from $183.5 million a year earlier, and normalized FFO of $0.38 per diluted share, up from $0.35. Net income attributable to Sabra fell to $0.16 per diluted share from $0.17, and the company reiterated its full-year 2026 guidance and declared a $0.30 quarterly dividend.
- Total revenues were $221.8 million for Q1 2026, compared with $183.5 million in Q1 2025.
- Normalized FFO was $0.38 per diluted share, compared with $0.35; normalized AFFO was $0.39, compared with $0.37.
- Net income attributable to Sabra was $40.9 million, or $0.16 per diluted share, compared with $40.3 million, or $0.17, a year earlier.
- The board declared a $0.30 quarterly dividend payable May 29, 2026, to holders of record on May 15, 2026; full-year 2026 guidance was reiterated.
Read the filing on SEC.gov ↗
Feb 12, 4:05 PM ET
Sabra Health Care REIT reported fourth quarter 2025 total revenues of $211.9 million, up from $182.3 million a year earlier, but diluted net income fell to $0.11 per share from $0.19. Normalized FFO rose to $0.36 per share from $0.35 and normalized AFFO rose to $0.38 from $0.36. The company also initiated 2026 guidance for normalized FFO of $1.49 to $1.53 per share and normalized AFFO of $1.55 to $1.59 per share.
- Q4 2025 diluted net income $0.11 per share vs $0.19 in Q4 2024; net loss on sales of real estate was $9.1 million in the quarter
- Q4 2025 normalized FFO $0.36 per share vs $0.35; normalized AFFO $0.38 vs $0.36
- 2026 guidance: net income $0.60 to $0.64 per share; normalized FFO $1.49 to $1.53; normalized AFFO $1.55 to $1.59
- Board declared a quarterly dividend of $0.30 per share, payable February 27, 2026 to holders of record on February 13, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
